Sinovac Biotech Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sinovac Biotech Ltd.
A new study in over 400 people reignites fears about the apparent low efficacy of Chinese COVID-19 vaccines, especially among the elderly, and adding to the debate around the need for booster shots.
There is talk about offering booster shots to people who have already been fully vaccinated against COVID-19 in China and it’s increasingly clear that the mRNA vaccine from BioNTech/Fosun nearing approval could be the answer. Meanwhile, some Asian countries are turning away from Chinese coronavirus vaccines.
Studies point to Johnson & Johnson, Pfizer and Bharat Biotech’s vaccines neutralizing the Delta variant of SARS-CoV-2, even if efficacy is lower compared to the original strain. This follows positive news from other vaccine companies but will the Lambda variant cause a setback?
Coronavirus Notebook: EMA Says ‘Wait And See’ On CureVac Data, EU Ministers Want Voluntary Approach To Sharing IP
AstraZeneca and the European Commission have both claimed victory in the Vaxzevria supply case brought against the company by the commission. The Moderna coronavirus vaccine is now under review by the European Medicines Agency for use in younger people.
- In Vitro Diagnostics
- Drug Delivery
- Implantable Devices
- Monitoring Equipment & Devices
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Beijing Kexing Bioproducts
- Sinovac Dalian Vaccine Technology Co., Ltd.
- Sinovac (Cayman) Limited